ArticleFrontiers in oncology2026
Adherence to adjuvant endocrine therapy in breast cancer: a single regional Australian centre experience.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Adjuvant endocrine therapy reduces cancer recurrence and improves overall survival in hormone receptor-positive breast cancer. Maintaining long-term adherence to endocrine therapy can be challenging, and non-adherence has been associated with higher recurrence rates and reduced survival. Despite its importance, data describing adherence patterns in regional Australian populations are limited. This study aimed to assess adherence to adjuvant endocrine therapy in a regional Australian cancer center and to examine factors associated with non-adherence. Methods: A cross-sectional survey was conducted at a regional Australian cancer center between March 2023 and July 2024. Eligible participants were women receiving adjuvant oral endocrine therapy for breast cancer. Adherence was assessed using the six-item Simplified Medication Adherence Questionnaire (SMAQ). Participants also reported treatment-related side effects. Results: One hundred women were included, with a median age of 62.5 years. The adherence rate as determined by the SMAQ was 65%. Participants reported an average of 2.5 treatment-related side effects, with hot flashes being the most commonly reported (59%). Both the presence and number of reported side effects were associated with lower adherence. In multivariable analyses, a higher side-effect burden remained associated with adherence after adjustment for other covariates. Discussion: This study demonstrates suboptimal adherence to adjuvant endocrine therapy in a regional Australian cohort and highlights treatment-related side effects and forgetfulness as key barriers to adherence. These findings underscore the importance of proactive side-effect management and practical adherence support strategies within regional cancer care settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.